

December 30, 2025

Company Name:	HEALIOS K.K.
Representative:	Hardy TS Kagimoto, Chairman & CEO (TSE Growth Code: 4593)
Contact:	Richard Kincaid, Executive Officer CFO (TEL: 03-4590-8009)

(Delayed) Notice Regarding the Filing of a Lawsuit Against Healios

HEALIOS K.K. (“Healios”) announced on December 29th that we became aware that a lawsuit was filed against Healios by AND medical group. Details are as follows.

1. Court and Date of Filing

- 1) Court: Tokyo District Court
- 2) Date Filed: November 27, 2025
- 3) Date of Service of Complaint to Our Company: December 26, 2025

2. Cause of Action and Background Leading to the Filing of the Lawsuit

AND medical group, a general incorporated association, has filed a lawsuit against, alleging that we are in default and have performed incompletely under the contract (“Joint Research Agreement with AND medical to Utilize Healios Technology and Culture Supernatan” announced on April 9, 2024) concluded between our company and said association.

3. Overview of the Entity Filing the Lawsuit

Name: AND medical group
Address: 6F Roppongi Trinity Building, 7-14-7 Roppongi, Minato-ku, Tokyo
Representative's Title and Name: Representative Director Masaomi Kusano

4. Details of the Lawsuit

- 1) Nature: Claim for Damages
- 2) Amount Claimed: 120,000,000 yen plus litigation costs, etc.

5. Future Outlook

Healios believes that it has properly fulfilled its obligations under the contract entered into with the plaintiff. It is the view of Healios that the plaintiff's claims are entirely without merit, and Healios will seek to establish the legitimacy of its position through the course of the proceedings in this litigation. Healios is advancing discussions with multiple reputable business partners regarding the sale of culture supernatant and there is no change to our current business policy at this time.

We will promptly announce any matters that should be disclosed in the future.